Press-release for stocks publishing date 2021 - 06

Prices are updated after-hours

| 218.25% | O: 0.01% H: 1.38% C: 0.49%
research

Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions And Weight Loss
Published: 2021-06-29 (Crawled : 17:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

| 218.25% | O: 0.01% H: 1.38% C: 0.49%
weight loss blood test trial tirzepatide

Eli Lilly’s Antibody Therapy for COVID-19 Paused in US and More COVID-19 News
Published: 2021-06-29 (Crawled : 16:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M

| -9.82% | O: -0.01% H: 0.39% C: 0.02%
LLY | News | $726.31 -2.63% -0.04% 3.5M

| 218.25% | O: 0.01% H: 1.38% C: 0.49%
covid therapy antibody covid-19

Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline
Published: 2021-06-29 (Crawled : 13:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M

| 218.25% | O: 0.01% H: 1.38% C: 0.49%
license technology

Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
Published: 2021-06-29 (Crawled : 12:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

| 218.25% | O: 0.01% H: 1.38% C: 0.49%
RIGL | $1.07 1.91% 1.87% 810K

| -75.84% | O: 3.36% H: 0.0% C: -3.68%
covid trial covid-19

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal
Published: 2021-06-29 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

| 218.25% | O: 0.01% H: 1.38% C: 0.49%
license technology

67%

33%

Save your searches and get alerts when important news are released.